AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02787135 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: emotion-oriented Cognitive Behavior Therapy
Description: Emotion-oriented Cognitive Behavior Therapy with a focus on delusions: Aim of the intervention is to change factors that are involved in the formation and maintenance of delusions: emotional stability and regulation of negative emotions, sleep quality and self-esteem.
Study NCT03162523 — intervention group
Intervention type: RADIATION
Intervention: High-Dose Rate Brachytherapy
Study NCT02950051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Fludarabine i.v.: cycles 1-6: 25 mg/m², d1-3, q28d
Study NCT02950051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide i.v.: cycles 1-6: 250 mg/m², d1-3, q28d
Study NCT02950051 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab i.v. (before chemotherapy): cycle 1: 375 mg/m², d0; cycles 2-6: 500 mg/m², d1; q28d
Study NCT02950051 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab i.v. (before chemotherapy): cycle 1: 375 mg/m², d0; cycles 2-6: 500 mg/m², d1; q28d
Study NCT02950051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Bendamustine i.v.: cycles 1-6: 90mg/m², d1-2, q28d
Study NCT02950051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax p.o. (ramp-up: dose escalation until final dose is reached)~cycle 1: 20 mg (2 tabl. at 10 mg), d22-28, q28d~cycle 2: 50 mg (1 tabl. at 50 mg), d1-7; 100 mg (1 tabl. at 100 mg), d8-14; 200 mg (2 tabl. at 100 mg), d15-21; 400 mg (4 tabl. at 100 mg), d22-28, q28d~cycles 3-12: 400 mg (4 tabl. at 100 mg), d1-28, q28d
Study NCT02950051 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab i.v.~cycle 1: 100 mg, d1; 900 mg, d1(2); 1000 mg, d8+15, q28d~cycles 2-6: 1000 mg, d1, q28d
Study NCT04139239 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coma Recovery Scale-revision
Description: Patients were assessed by Coma Recovery Scale-revision to detect the DOC patients enrolled by clinicians.
Study NCT03623399 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: low gas pressure laparoscopy
Description: To apply different CO2 entrance and intraoperative pressures
Study NCT04397497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavrilimumab
Description: human monoclonal antibody targeting GM-CSF receptor-alpha
Study NCT04397497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching volume of diluent
Study NCT03770754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clean and shape Control group
Description: For the control group the root canals were prepared manually with K-files and step back technique up to size #35. For this group were administered Tylenol
Study NCT03770754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cleand and shape Group 1
Description: For the Group 1, LightSpeed LSX rotary instruments (Discus Dental, Culver City, CA, USA) were used to complete the canal preparation to a size #50 for the anteriors and molars to size #40. After procedures were administered Tylenol
Study NCT03770754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clean and shape Group 2
Description: For the group 2 the root canals were instrumented with ProTaper ﬁles using X1, X2 (21mm) to X3 (21mm). 0.5% NaOCl was used for irrigation, the original protocol suggested by ProTaper for permanent teeth was simplified for this study.~After clinical procedures Tylenol were administered
Study NCT02523508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Subject will be put into lying position, small amplitude of passive movement on the lumbar spine of the subject. The procedure will last for 1 minute.
Study NCT02523508 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Passive limb mobilization which did not involve the spine
Study NCT02609971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration at 50 Hz
Description: During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 50 Hz.
Study NCT03704025 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Current guidelines rehabilitation
Description: Exercise training intervention is six months and includes four to five aerobic and two strength training session a week according to American Heart Association guidelines for coronary artery disease patients. All the patients will have a detailed and personalized training diary.
Study NCT02950051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib p.o.~cycles 1-12: 420 mg, d1-28, q28d~cycles 13-36: 420 mg, d1-28, q28d
Study NCT01611701 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryoballoon ablation
Description: In Cryo group, 28mm balloon was introduced into the PV ostium with the best possible occlusion of the PV. Every step was controlled by fluoroscopy. Cryoenergy was applied for maximal 6 minutes per application for 2 times, resulting in a circumferential ablation lesion. Before the right superior vein was treated, a quadripolar catheter was placed in the superior vena cava to continuously stimulate the right phrenic nerve during cryoapplication. The application was stopped immediately in the case of diminished diaphragm movements.
Study NCT01611701 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: n RF group, reisolation of the PV was performed by identifying the breakthrough site. Radiofrequency energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s.
Study NCT03254082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glycemic response of F-1000
Description: The intervention was to determine if different flours elicit similar or different (change from baseline) 2 hour glucose responses (e.g., similar to glycemic index) after eating.
Study NCT03254082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glycemic response to sumac sorghum flour
Description: The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming sumac sorghum flour as a gruel.
Study NCT03254082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glycemic response to MMR sorghum flour
Description: The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming MMR sorghum flour as a gruel.
Study NCT03254082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glycemic response to wheat flour
Description: The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming wheat flour as a gruel.
Study NCT03254082 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glycemic response to sucrose
Description: The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming sugar (dissolved in water)
Study NCT05420155 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical resection
Description: Surgical treatment of hepatic hydatidic cyst
Study NCT02111590 — intervention group
Intervention type: DRUG
Intervention: Immunoglobulins
Description: SCIG dosage is individualized for each patient according to previous IVIG dosage
Study NCT00959933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)
Study NCT00959933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebetol 200 Capsules (Schering Corporation, U.S.A.)
Study NCT02897713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intensive enteral nutrition
Description: After recruitment, patients should be assessed for EN initiation during first 24 hours after ICU admission. 80% of energy target should be reached within 72 hours.
Study NCT02897713 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine enteral nutrition
Description: Attendings decide when and how EN should be administered according to guidelines from academic organizations, such as ESPEN or ASPEN.
Study NCT01339585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Eldith Direct Current Stimulator (NeuroConn GmbH, Germany)
Study NCT02863926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of cBMA aspirate into the index leg
Description: Injection of cBMA into the anterior tibialis muscle and upper index leg of subjects scheduled for semi-elective BKA 7-21 days before surgery
Study NCT04546308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: Eight weeks whole-body resistance exercise training (80%1 repetition maximal, 3 sessions per week) followed by a 4-week detraining intervention
Study NCT00605293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta
Description: 120, 200 or 360 micrograms iv/month (starting dose)
Study NCT00605293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa
Description: As prescribed
Study NCT01404520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise based multimodal intervention
Description: The intervention is initiated early, during treatment (consolidation) in the intra-hospital setting and continues for two successive treatment series (12 weeks). The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and health-promoting consultation combined with an unsupervised in-home walking and progressive relaxation programme.
Study NCT02852551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAT-1251
Study NCT02852551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02852551 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01043770 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group lifestyle education
Description: Structured group education programme based on lifestyle changes (dietary and increased physical activity)
Study NCT02019160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25% AgNO3 solution followed by 5% NaF varnish
Description: Dosage of 4.4μg±1.4μg fluoride per use
Study NCT02019160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 38% SDF solution followed by placebo varnish
Description: Dosage of 8.8μg±2.8μg fluoride per use
Study NCT00454051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Omalizumab was supplied as a sterile, freeze dried preparation, to be reconstituted to deliver 150mg of omalizumab. Each vial was reconstituted with 1.4ml of sterile water for injection. The appropriate dose and dosing frequency of omalizumab were determined by baseline total IgE and body weight. A dosing table was used following the European Summary of Product Characteristics (SmPC) of omalizumab.
Study NCT00454051 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo was a physiological salt solution, administered according to the same administration scheme to respect the same dosing frequency and injected volume.
Study NCT02025881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin + etoposide
Description: Carboplatin 160 mg/m\^2 Day 1 to day 5, as an intravenous infusion over 1 hour. Dilution in 5 % glucose saline or sodium chloride 9 mg/ml (0.9%).~Etoposide 100 mg/m\^2 D ay 1 to day 5, as an intravenous infusion over 1 hour. Dilution in physiological saline or 5 % glucose saline while not exceeding a concentration of 0.4 mg/ml etoposide in the infusion bottle.
Study NCT02025881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa 200 mg/m² Day-3 to day-1, as an intravenously infusion over 1 hour dilution in 200 ml/m\^2 of 5% glucose saline or sodium chloride 9 mg/ml (0.9%).
Study NCT02025881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide + Busilvex
Description: Cyclophosphamide:~* Level 1 20 mg/kg/day~* Level 2 30 mg/kg/day~* Level 3 40 mg/kg/day~* Level 4 50 mg/kg/day~Busilvex:~\< 9 kgs 0.8 mg/kg/dose -> 3.2 mg/kg/day; 9 à \< 16 kgs 0.96 mg/kg/dose -> 3.84 mg/kg/day; 16 à 23 kgs 0.88 mg/kg/dose -> 3.52 mg/kg/day; > 23 à 34 kgs 0.76 mg/kg/dose -> 3.04 mg/kg/day; > 34 kgs -> 0.64 mg/kg/dose.
Study NCT02025881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolimide + Irinotecan
Description: During 2 cycles of 21 days:~* Temozolomide: 100 mg/m\^2/day PO from Day 1 to Day 5;~* Irinotecan: 10 mg/m\^2/day IV from Day 1 to Day 5 + from Day 8 to Day 12
Study NCT02025881 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Etoposide + radiotherapy
Description: * Etoposide: 35 mg/m\^2/day PO during 21days~* Radiotherapy: 1.8 Gy/fraction/day (total dose: 54 Gy)
Study NCT02025881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 150 mg/m\^2/day PO during 5 days, during 6 cycles of 21 days
Study NCT03529474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychology and Physiotherapy group
Description: Psychological program: 4 sessions,2 hours each,4 months~* Psychoeducation.Influence of psychological factors on chronic pain: modulators of pain experience. Biopsychosocial model of pain.~* Training techniques of psychological management of pain:Diaphragmatic Breathing and Progressive Muscle Relaxation to control vicious circle pain-tension-pain.~* Kinesiophobia. Rational regulation of the activity level:Cognitive therapy (management of irrational believes about pain) and Organisation of time and reinforcement activities.~Physiotherapy program:3 sessions per week,1 hour per session,4 months:~* Aerobic exercise:walking, cycling~* Warm-up: active ROM exercises of inferior and superior extremities (ISE)~* Progressive resistance training with elastic bands of ISE~* Stretching of ISE
Study NCT03529474 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator: control group
Description: Control group Normal daily activities Usual daily activities
Study NCT03704025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile device guided rehabilitation
Description: Exercise training intervention is six months and includes four to five aerobic and two strength training session a week according to American Heart Association guidelines for coronary artery disease patients. Study group will have virtual glasses or mobile device to motivate and control exercise training program.
Study NCT03130400 — intervention group
Intervention type: PROCEDURE
Intervention: Observational gait analysis procedure
Description: All the participants underwent a standard observational procedure: i) diagnosed with knee injuries/arthritis; ii) For KOA, take radiographic examination (x-ray) and take gait analysis on a treadmill in barefoot; iii) For knee injuries, take gait analysis before surgery, the disease of patients was confirmed by surgery (knee arthroscopy); iv)Normal people take an physical examination to avoid other disease;
Study NCT00404547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: Asthma Care with Alvesco
Study NCT00404547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Inhaled Glucocorticosteroids
Description: Usual asthma care and dosage as chosen by the Primary Care Physician including inhaled steroid treatment
Study NCT04117906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAGE training for anxiety
Description: STAGE is a brief, online, self-help course designed to target anxiety through providing training in perspective broadening and self-distancing.
Study NCT04130373 — intervention group
Intervention type: PROCEDURE
Intervention: Autologous fat grafting procedure
Description: Surgical intervention based on the injection of autologous fat grafting after radical or conservative breast surgery and breast reconstruction.
Study NCT04130373 — intervention group
Intervention type: PROCEDURE
Intervention: Breast reconstruction
Description: Breast reconstructive procedures after oncological radical or conservative breast surgery
Study NCT03892122 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Propofol Fresenius
Description: Propofol will be infused with TCI (Target Controlled Infusion) pump. TCI system has been developed to provide improved convenience and control during intravenous anaesthesia. The basic principle is that the anesthetist sets and adjusts the target blood concentration- and depth of anesthesia-as required on clinical grounds.~Infusion rates are altered automatically according to a validated pharmacokinetic model. TCI technology uses different pharmacokinetic modeling to control the infusion rate of the pump, which allows for a direct control of the sedative agent brain concentration rather than its blood concentration. (de vito 2017) The development of target-controlled infusion (TCI) technology has increased the number of indications for propofol sedation in clinical practice. Furthermore, several studies have demonstrated that propofol-based TCI allows for the accurate control of sedation during DISE and results in an authentic reproduction of the sleep process.
Study NCT03892122 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: is a selective alpha-2 adrenergic receptor agonist, which seems to act on the locus coeruleus (LC) or to the preoptic hypothalamus to decrease wakefulness, with almost no effect on respiratory depression. Dexmedetomidine exerts its hypnotic action through activation of central pre- and postsyn¬aptic alpha2-receptors in the locus coeruleus, thereby inducting a state of unconsciousness similar to natural sleep, with the unique as¬pect that patients remain easily arousable and cooperative. Comparing with propofol, dexmedetomidine provides a state of sedation closer to natural sleep and lesser upper airways muscular relaxing effect, even at the increased anesthetic dosage Otherwise, Dexmedetomidine is characterized by a slightly longer onset of action (5-10 minutes), and patients take longer timing to recover..The sedative action of Dexmedetomidine can be reached by means of infusion technique (starting dose: 1 μg/kg over 10 minutes; maintenance infusion rate: 0,7 μg/kg/h).
Study NCT01243398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study NCT01243398 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Study NCT04455412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Assisted ICSI
Description: using OCTICS laser device to do small opening or zona thinning to improve ICSI outcome
Study NCT01188330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WITH Comprehensive Geriatric assessment
Description: Each month after randomization, a nurse practitioner will systematically review the intervention plan.~In case of hospitalisation, the nurse will go and meet the patient and his care giver to check each point of the intervention plan. If an action has not been done, a new proposal will be made to the patient. If the patient is at home or in institution, the nurse practitioner will call the patient and /or his care giver for the same purpose
Study NCT01188330 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: no Comprehensive Geriatric assessment
Study NCT00833105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMES treatment
Description: The AMES device rotates the fingers-thumb or the wrist in the flexion-extension directions over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that are lengthened by the thumb-finger or hand movement. A treatment consists of 20 minutes of fingers-thumb movement, followed by 10 minutes of wrist movement. The subject's task is to assist the motion of the device.
Study NCT01668173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Description: AUY922 will be administered as an intravenous infusion over 60 minutes, on a once weekly schedule. A cycle on study will be defined as 28 days. The dose to be studied are 70 mg/m2 and 55 mg/m2 if DLTs are identified in the first 3-6 patients. The same schedule of administration will be used for all patients in this trial.
Study NCT03864679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Subjects will perform a cycling test with 5 min incremental intensity exercise and 1 h cycling test exercising at a moderate-intensity (load will be selected in incremental intensity exercise).
Study NCT03759587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib capsule
Study NCT02737930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Study NCT02737930 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02497560 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: proprietary formula
Study NCT02497560 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: proprietary formula
Study NCT02497560 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: proprietary formula
Study NCT02166060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Ivabradine 5 mg twice a day or 7,5 mg twice a day